Passion & Purpose in Women's Oncology

Our lead candidate is Lasofoxifene

 
 

About

Sermonix Pharmaceuticals, founded in late 2014 by David Portman, MD, a leading clinical researcher and expert in women’s health, menopause and selective estrogen receptor modulators, is a privately held biotechnology company focused on the development and commercialization of female-specific oncology products.

 
Read more

Lasofoxifene

Extensively studied, Sermonix is investigating Lasofoxifene for breast and ovarian cancer treatments. Demonstrated efficacy in reducing the incidence of ER+ breast cancer in women with osteoporosis.

 
Read more

News

SERMONIX PHARMACEUTICALS SIGNS EXCLUSIVE LICENSING AGREEMENT TO FURTHER EXPLORE LASOFOXIFENE FOR BREAST CANCER TREATMENT.

 
Read more
Seventy percent of the 240,000 U.S. women diagnosed with breast cancer are ER+ positive. LEARN MORE